Medicine
Dasatinib
Nilotinib
Myeloid leukemia
Internal medicine
Imatinib
Hazard ratio
Univariate analysis
Oncology
Imatinib mesylate
Population
Proportional hazards model
Myeloproliferative neoplasm
Immunology
Multivariate analysis
Bone marrow
Confidence interval
Myelofibrosis
Environmental health
